ArticleHepatology international2025
Hepatic immune-related adverse event increased the overall survival of patients with malignancies treated with immune checkpoint inhibitors.
Article in Hepatology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Reply to letter to editor "Hepatic irAEs, ICI Continuation, and Survival: Methodological Perspectives and Future Directions".Hepatology international · 2026Article
- Hepatic irAEs, ICI continuation, and survival: methodological perspectives and future directions.Hepatology international · 2026Article
- Antiviral therapy and the risk of extrahepatic malignancies in chronic hepatitis C: insights from recent evidence.Translational cancer research · 2026Article
- Immune-checkpoint inhibitors for advanced hepatocellular carcinoma in Child-Turcotte-Pugh-B cirrhosis: a liver-centric approach to outcomes beyond tumor progression.Hepatology international · 2026Review
- Risk factors and outcomes for steroid-refractory immune-related hepatotoxicity in locally advanced and metastatic cancer.Cancer immunology, immunotherapy : CII · 2026Article
- Revisiting the safety profile of tenofovir alafenamide: methodological reflections on real-world data.Hepatology international · 2025Article
- Tenofovir alafenamide-related hyperlipidemia and cardiovascular risk.Hepatology international · 2025Article
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
aimAssociations between the occurrence of abnormal liver function tests, an immune-related adverse event (irAE) caused by immune checkpoint inhibitors (ICIs), and treatment efficacy are unclear. We investigated the association between the incidence of these hepatic irAE occurrences and treatment response in patients treated with ICIs.
methodsWe studied 924 patients treated with ICIs to determine the relationship between the incidence of irAEs and overall survival (OS) with and without the continuation of ICIs due to hepatic irAEs.
resultsOf 924 treated, 338 (36.6%) developed all types of irAEs. Median OS for patients with and without irAEs were 34.3 months (n = 338) and 13.1 months (n = 586), respectively (p = 2.49 × 10
conclusionsIn patients who developed hepatic irAEs, OS was longer in the continued treatment group than in the discontinued treatment group. Most patients who developed hepatic irAEs and stopped the treatment had higher aminotransferase, but often lacks the stigmata of impending hepatic failure such as prothrombin time prolongation or gradual elevation of total bilirubin. Multi-disciplinary cooperation, including hepatologists, may be important for OS improvement by the prolonged use of ICIs.
Indexed as
Identifiers
40198524What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.